Met Life Investment Management, LLC Biotechnology

Met Life Investment Management, LLC

$18 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
MGNX Macrogenics Inc	$102M	$128,000 0.0% of portfolio	39,669	Q4 2024 Added 162.83%
AVIR Atea Pharmaceuticals, Inc.	$241M	$124,000 0.0% of portfolio	37,091	Q4 2024 Reduced 17.94%
CADL Candel Therapeutics, Inc.	$143M	$119,000 0.0% of portfolio	13,773	Q4 2024 Added 9.68%
DSGN Design Therapeutics, Inc.	$217M	$119,000 0.0% of portfolio	19,334	Q3 2024 New
CRDF Cardiff Oncology, Inc.	$122M	$115,000 0.0% of portfolio	26,559	Q4 2024 New
XOMA Xoma Corp	$273M	$114,000 0.0% of portfolio	4,371	Q2 2024 Added 10.38%
HRTX Heron Therapeutics, Inc.	$273M	$111,000 0.0% of portfolio	72,690	Q4 2024 Added 0.88%
TSHA Taysha Gene Therapies, Inc.	$84.6M	$108,000 0.0% of portfolio	62,990	Q4 2024 Reduced 17.16%
ITOS I Teos Therapeutics, Inc.	$261M	$107,000 0.0% of portfolio	14,043	Q2 2024 Added 10.77%
ABSI Absci Corp	$291M	$104,000 0.0% of portfolio	39,857	Q4 2024 Reduced 17.9%
MRSN Mersana Therapeutics, Inc.	$35M	$104,000 0.0% of portfolio	73,150	Q4 2024 Added 115.68%
CCCC C4 Therapeutics, Inc.	$75.3M	$103,000 0.0% of portfolio	28,854	Q4 2024 Reduced 18.62%
CHRS Coherus Bio Sciences, Inc.	$80.1M	$100,000 0.0% of portfolio	73,099	Q4 2024 New
FENC Fennec Pharmaceuticals Inc.	$148M	$99,000 0.0% of portfolio	15,676	Q4 2024 New
NKTR Nektar Therapeutics	$146M	$99,000 0.0% of portfolio	106,506	Q3 2024 Added 129.07%
CMPX Compass Therapeutics, Inc.	$220M	$91,000 0.0% of portfolio	63,141	Q4 2024 Added 200.3%
ALLO Allogene Therapeutics, Inc.	$223M	$80,000 0.0% of portfolio	38,020	Q4 2024 Reduced 28.46%
LRMR Larimar Therapeutics, Inc.	$102M	$70,000 0.0% of portfolio	18,428	Q4 2024 Reduced 25.71%
ZNTL Zentalis Pharmaceuticals, Inc.	$81.5M	$69,000 0.0% of portfolio	22,971	Q4 2024 Reduced 32.62%
INZY Inozyme Pharma, Inc.	$38.9M	$66,000 0.0% of portfolio	23,958	Q4 2024 Reduced 14.28%
TSVT 2seventy Bio, Inc.	$189M	$61,000 0.0% of portfolio	20,967	Q4 2024 Reduced 29.31%
ADCT Adc Therapeutics Sa	$103M	$61,000 0.0% of portfolio	31,117	Q4 2024 Reduced 27.78%
TNGX Tango Therapeutics, Inc.	$129M	$60,000 0.0% of portfolio	19,631	Q4 2024 Reduced 30.54%
VTYX Ventyx Biosciences, Inc.	$67.8M	$58,000 0.0% of portfolio	26,731	Q4 2024 Added 76.0%
SANA Sana Biotechnology, Inc.	$337M	$45,000 0.0% of portfolio	27,658	Q4 2024 Reduced 64.36%
STRO Sutro Biopharma, Inc.	$57.4M	$43,000 0.0% of portfolio	23,390	Q4 2024 Reduced 24.3%
CRBU Caribou Biosciences, Inc.	$46.8M	$38,000 0.0% of portfolio	24,404	Q4 2024 Added 59.96%
FATE Fate Therapeutics Inc	$124M	$27,000 0.0% of portfolio	16,641	Q4 2024 Reduced 60.98%
PROK Prokidney Corp Ord Shs Cl A(Cy	$62.8M	$13,000 0.0% of portfolio	7,918	Q4 2024 Reduced 87.36%
ALEC Alector, Inc.	$94.1M	$10,000 0.0% of portfolio	5,468	Q4 2024 Reduced 89.14%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	33,086	Q4 2024 Added 12.86%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.